HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Looks To “Exploit” Switches With Exit From J&J Joint Venture

This article was originally published in The Tan Sheet

Executive Summary

Merck gains flexibility to pursue Rx-to-OTC switches, such as allergy drug Clarinex and cholesterol treatment Zetia by exiting its OTC joint venture with Johnson & Johnson.

You may also be interested in...



J&J Brand Revival Plan Relies On Marketing, Delivery Innovation

Johnson & Johnson expects innovation and marketing to restore consumer confidence in its OTC brands and drive a market-share rebound even as its U.S. sales continue to fall, dropping nearly 25% in its latest quarter.

Asthma Treatment OTC Switches Would Face Tough Barriers

Prescription asthma drugs on the brink of patent expiry could breathe new life into Rx-to-OTC switches, but not without fierce opposition from some health care providers.

J&J’s Caruso Pitches OTC Comeback To Analysts

Johnson & Johnson will not “shortchange” its commitment to returning its recalled consumer brands to the marketplace, Chief Financial Officer Dominic Caruso says.

Related Content

Topics

UsernamePublicRestriction

Register

RS134231

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel